This is the PDF eBook version for Staphylococcus Aureus – Molecular and Clinical Aspects By Dlawer Ala’ Aldeen, Keiichi Hiramatsu
Table of Contents
Chapter contributors
Preface
Chapter 1. Staphylococcal Infection: Emerging Clinical Syndromes
1.1 INTRODUCTION
1.2 BACTERAEMIA
1.3 ENDOVASCULAR INFECTION
1.4 BREAST INFECTIONS
1.5 CELLULITIS
1.6 DENTAL
1.7 DIALYSIS-RELATED INFECTIONS
1.8 EYE INFECTIONS
1.9 ENTEROCOLITIS
1.10 INTRA-ABDOMINAL
1.11 CENTRAL NERVIOUS SYSTEM
1.12 MYOCARDITIS/ PERICARDITIS
1.13 NASAL COLONIZATION
1.14 OSTEOMYELITIS/DISCITIS/ DIABETIC FOOT
1.15 PAROTITIS
1.16 RESPIRATORY INFECTIONS
1.17 SURGICAL SITE INFECTIONS
1.18 SMALL COLONY VARIANTS OF SA
1.19 TOXIC SHOCK SYNDROME
1.20 URINARY TRACT INFECTION
1.21 VASCULAR INFECTIONS
1.22 CONCLUSION
ACKNOWLEDGMENT
REFERENCES
Chapter 2. Epidemiology of MRSA and MSSA
2.1 RESERVOIRS
2.2 THE POPULATION STRUCTURE OF S. AUREUS
2.3 ROUTES OF TRANSMISSION
2.4 THE HOST POPULATION
2.5 CONCLUSIONS
REFERENCES
Chapter 3. The Staphylococcus aureus Genome
3.1 INTRODUCTION
3.2 PHYSICAL PROPERTIES OF S. AUREUS GENOME
3.3 FUNCTIONAL ORGANIZATION OF S. aureus GENOME
3.4 POLYMORPHISM OF S. AUREUS GENOME AND GENOME ALLOTYPING
3.5 CONCLUSION
ACKNOWLEDGEMENT
REFERENCES
Chapter 4. Virulence Gene Regulation and their role in pathogenesis of disease
4.1 INTRODUCTION
4.2 THE ACCESSORY GENE REGULATOR, agr.
4.3 THE SarA FAMILY OF TRANSCRIPTION FACTORS
4.4 SIGMA FACTOR B
4.5 TWO-COMPONENT SIGNAL TRANSDUCTION SYSTEMS
4.6 ROLE OF VIRULENCE REGULATORS IN INFECTION
REFERENCES
Chapter 5. Pathogenesis of disease
5.1 INTRODUCTION
5.2 S. AUREUS ENCAPSULATION
5.3 BIOFILM FORMATION
5.4 ADHERENCE
5.5 COLONIZATION
5.6 IRON ACQUISITION
5.7 INTERNALIZATION OF S. AUREUS BY NON-PROFESSIONAL PHAGOCYTES
5.8 STAPHYLOCOCCAL EXOTOXINS
ACKNOWLEDGEMENTS
REFERENCES
Chapter 6. Antimicrobial Resistance and Therapy of Staphylococcus aureus Infections
6.1 BASIC MECHANISMS OF RESISTANCE
6.2 BETA-LACTAM ANTIBIOTICS
6.3 GLYCOPEPTIDES
6.4 MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
6.5 LINEZOLID
6.6 FLUOROQUINOLONES
6.7 RIFAMPIN
6.8 MISCELLANEOUS AGENTS
6.9 THERAPEUTIC CONSIDERATIONS
REFERENCES